Tennessee bans DXM cough syrup sales to minors
WASHINGTON – Tennessee on Wednesday became the eighth state to restrict the sale of dextromethorphan to adults as Tennessee Gov. Bill Haslam signed HB0039 into law. The legislation, initially introduced by Sen. Ferrell Haile, R-Gallatin, and Rep. William Lamberth, R-Cottontown, was passed by the Senate on March 26 by a vote of 92-1.
“Stopping direct sale of OTC cough medicine to teens is a critical prevention measure, as it will put an end to a common way many abusers obtain the medicine – purchasing it themselves," stated Scott Melville, CHPA president and CEO. "Once enacted as law, this legislation also has the potential to raise awareness among parents and community leaders who are unaware of this dangerous behavior. We hope that this boost in awareness will mobilize parents and community leaders to have conversations with teens about the side effects of abusing all medicines including OTC cough medicine.”
CHPA advocates for state laws as well as a federal law prohibiting the sale of DXM products to minors. Kentucky most recently passed similar legislation in March.
Alignment Healthcare, Vivify Health partner on telemedicine platform
PLANO, Texas — Population health management company Alignment Healthcare has partnered with Vivify Health to provide a secure, remote care platform for its patients, the companies announced Thursday. Vivify, whose solutions impact high risk and rising risk populations, is designed to engage patients in their own health and shape desired behavior, thereby reducing risk for unplanned utilization of costly services.
Each Vivify kit contains a wireless-enabled Samsung tablet paired in advance with bluetooth-enabled peripheral health devices such as a scale, blood pressure device and pulse oximeter. AHC deploys the Vivify kit directly to the patient during their visit to their local AHC care center. Once home with the kit, the patient enjoys an “instant-on” experience by pushing one button to initiate their customized care plan from the cloud.
Guided by a customized care plan, biometric data from these bluetooth-enabled health devices combined with responses to daily assessments are transmitted wirelessly from the tablet to the Alignment Healthcare Command Center. This enables proactive monitoring of each patient’s health status through the management of automatically triggered alerts. Opportunities for intervention vary and can include virtual visits between the AHC Command Center and the patient in their home. The embedded video conferencing solution can even accommodate multi-party virtual visits when others need or wish to join, e.g. patient’s adult children, other family members, additional providers, etc.
“We are committed to providing our patients with the most advanced, easy to use technology that will serve as an extension to the care we provide patients in our care centers,” stated Ken Kim, chief medical officer at Alignment Healthcare. “It’s important we proactively monitor our patients and engage with them to ensure their health is being properly managed at home. If their clinical condition exacerbates, we’ll see the alerts and can take the appropriate measures to intervene as necessary. Vivify’s technology and unique approach to patient engagement definitely impressed us.”
The Vivify SaaS platform delivers the next generation of direct-to-consumer care: joining cloud computing, consumer-grade electronics and a user interface that facilitates adoption across all demographics, regardless of patients’ technical abilities. This solution, coupled with the AHC-managed patient monitoring portal for efficient alert management and opportunity for immediate intervention, sets the table for directly impacting patient care in the home and reducing risk for hospital admissions and re-admissions.
According to Kerry Matsumoto, chief information officer at Alignment Healthcare, “The entire data flow is fully encrypted and secure from the in-home patient device to the tablet, through to the Vivify Portal and arrives real-time into the AHC Command Center portal. We selected Vivify due to the simplicity of their platform for use by the patient and our clinicians, the continued innovation plans for the product, the security and rigor of the technology, and our expected improvement in clinical outcomes. The initial product launch has already yielded positive comments from patients on ease of use and eagerness to be monitored at home.”
Mylan makes $29 billion bid for Perrigo
POTTERS BAR, England — Mylan on Wednesday announced that it has made a proposal to acquire Perrigo in a $29 billion cash-and-stock transaction that would create a diversified, global pharmaceutical leader with an unmatched commercial and operating platform and a unique, one-of-a-kind profile. The combination of these complementary businesses would produce a company with critical mass in specialty brands, generics, over-the-counter and nutritional products and a commercial platform with reach across all customer channels, the company stated.
Under the terms of the non-binding proposal, Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for each Perrigo share, which represents a greater than 25% premium to the Perrigo trading price as of the close of business on April 3, 2015 (the last trading date prior to the date of Mylan's proposal), a greater than 29% premium to Perrigo's sixty-day average share price and a greater than 28% premium to Perrigo's ninety-day average share price.
"This proposal is the culmination of a number of prior discussions between Mylan and Perrigo about the compelling strategic and financial logic of this combination," stated Robert Coury, Mylan executive chairman. "This combination would result in meaningful immediate and long-term value creation, and our proposal is designed to deliver that value to shareholders and other stakeholders of both companies. We have great respect for Perrigo's board and management team and what they have built. We look forward in the weeks ahead to working with them to capitalize on this tremendous opportunity and working together to create a unique leader with a one-of-a-kind profile in our industry."
The proposal is subject to the pre-condition of confirmatory due diligence, which pre-condition may be waived by Mylan at its discretion. This announcement is not an announcement of a firm intention to make an offer under rule 2.5 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 and there can be no certainty that an offer will be made, even if the due diligence pre-condition is satisfied or waived. A further statement will be made if and when appropriate.
Loading Post Please Wait...